{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:24:55Z","timestamp":1789010695230,"version":"build-2803163510"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objectives:<\/jats:bold> This study aims to investigate adverse events (AEs) and adverse drug reactions (ADRs) associated with pirfenidone and nintedanib, two antifibrotic drugs used to treat idiopathic pulmonary fibrosis (IPF).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Reporting odds ratio (ROR) and proportional reporting ratio (PRR) analyses were conducted to assess the association between these drugs and signals at both the preferred term (PT) and system organ class (SOC) levels.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> 55,949 reports for pirfenidone and 35,884 reports for nintedanib were obtained from the FAERS database. The VigiAccess database provided 37,187 reports for pirfenidone and 23,134 reports for nintedanib. Male patients and individuals over the age of 65 were more likely to report AEs. Gastrointestinal disorders emerged as the most significant signal at SOC level for both drugs. Furthermore, nausea, diarrhoea, and decreased appetite were observed at the PT level. We further identified notable signals, including hemiplegic migraine for pirfenidone and asthenia, constipation, and flatulence for nintedanib, which were previously unknown or underestimated ADRs.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This study has identified AEs and ADRs associated with pirfenidone and nintedanib, confirming that the majority of the corresponding label information indicates relative safety. However, it is essential to take unexpected risk signals seriously, necessitating further research to manage the safety profiles of these drugs.<\/jats:p>","DOI":"10.3389\/fphar.2024.1310286","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T04:57:37Z","timestamp":1708664257000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["A real-world study of antifibrotic drugs-related adverse events based on the United States food and drug administration adverse event reporting system and VigiAccess databases"],"prefix":"10.3389","volume":"15","author":[{"given":"Menglin","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taoran","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rurong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/bjc.2015.374","article-title":"Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours","volume":"113","author":"Bahleda","year":"2015","journal-title":"Br. J. Cancer"},{"key":"B2","article-title":"Artificial intelligence for drug toxicity and safety","author":"Basile","year":"2023"},{"key":"B3","article-title":"OpenVigil FDA - inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications","author":"B\u00f6hm","year":"2023"},{"key":"B4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S2213-2600(18)30339-4","article-title":"Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON","volume":"7","author":"Crestani","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"B5","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","author":"Evans","year":"2023"},{"key":"B6","volume-title":"Reporting adverse drug events","author":"Feagins","year":"2023"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1800230","DOI":"10.1183\/13993003.00230-2018","article-title":"Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis","volume":"52","author":"Flaherty","year":"2018","journal-title":"Eur. Respir. J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"New Engl. J. Med."},{"key":"B9","article-title":"Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation","author":"Justet","year":"2023"},{"key":"B10","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1025947","article-title":"Clinical outcomes of dose modification during pirfenidone treatment for IPF: a nationwide post-marketing surveillance study","author":"Kang","year":"2023"},{"key":"B11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12931-023-02551-x","article-title":"Expression of PD-1\/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis","volume":"24","author":"Karampitsakos","year":"","journal-title":"Respir. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"104766","DOI":"10.1016\/j.ebiom.2023.104766","article-title":"Precision medicine advances in idiopathic pulmonary fibrosis","volume":"95","author":"Karampitsakos","year":"","journal-title":"EBioMedicine"},{"key":"B13","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/MCP.0000000000000977","article-title":"Management of patients with idiopathic pulmonary fibrosis and lung cancer: challenges in clinical practice","volume":"29","author":"Karampitsakos","year":"","journal-title":"Curr. Opin. Pulm. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/resp.14363","article-title":"Lung cancer in patients with idiopathic pulmonary fibrosis: a retrospective multicentre study in Europe","volume":"28","author":"Karampitsakos","year":"","journal-title":"Respirology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"170057","DOI":"10.1183\/16000617.0057-2017","article-title":"Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis","volume":"26","author":"Lancaster","year":"2017","journal-title":"Lid. -"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"Lederer","year":"2018","journal-title":"New Engl. J. Med."},{"key":"B17","article-title":"Novel drug delivery systems and disease models for pulmonary fibrosis","author":"Li","year":"2023"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e066354","DOI":"10.1136\/bmj-2021-066354","article-title":"Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis","volume":"377","author":"Liu","year":"2022","journal-title":"BMJ"},{"key":"B19","article-title":"Role of pirfenidone in the management of pulmonary fibrosis","author":"Meyer","year":"2023"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2200380","DOI":"10.1183\/13993003.00380-2022","article-title":"Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial","volume":"60","author":"Otsubo","year":"2022","journal-title":"Eur. Respir. J."},{"key":"B21","article-title":"Impact of antifibrotic therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis: a systematic review and meta-analysis","author":"Petnak","year":"2023"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2200957","DOI":"10.1183\/13993003.00957-2022","article-title":"Idiopathic pulmonary fibrosis: state of the art for 2023","volume":"61","author":"Podolanczuk","year":"2023","journal-title":"Eur. Respir. J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40248-019-0197-0","article-title":"Clinical course and management of idiopathic pulmonary fibrosis","volume":"14","author":"Quinn","year":"2019","journal-title":"Multidiscip. Respir. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1801060","DOI":"10.1183\/13993003.01060-2018","article-title":"No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone","volume":"53","author":"Richeldi","year":"2019","journal-title":"Eur. Respir. J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1007\/s12094-021-02661-2","article-title":"Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma","volume":"23","author":"Riudavets","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"B26","article-title":"Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis","author":"Rogliani","year":"2023"},{"key":"B27","doi-asserted-by":"publisher","first-page":"15673","DOI":"10.1111\/bcp","article-title":"A post-marketing pharmacovigilance study of avapritinib: adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database","author":"Rong","year":"2023","journal-title":"Lid. -"},{"key":"B28","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","author":"Rothman","year":"2023"},{"key":"B29","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1165\/rcmb.2019-0328TR","article-title":"Pirfenidone: molecular mechanisms and potential clinical applications in lung disease","volume":"62","author":"Ruwanpura","year":"2020","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/resp.13647","article-title":"Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: results from INPULSIS\u00ae-ON","volume":"25","author":"Song","year":"2019","journal-title":"Respirology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41591-020-0766-y","article-title":"A patient-researcher partnership for rare cancer research","volume":"26","author":"Staniszewka","year":"2020","journal-title":"Nat. Med."},{"key":"B32","article-title":"Differential discontinuation profiles between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis","author":"Takehara","year":"2023"},{"key":"B33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3389\/fmed.2020.00029","article-title":"Impact of depression on patients with idiopathic pulmonary fibrosis","volume":"7","author":"Tzouvelekis","year":"2020","journal-title":"Front. Med. (Lausanne)"},{"key":"B34","article-title":"Targeting fibrosis, mechanisms and cilinical trials","author":"Zhao","year":"2023"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1310286\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T04:57:40Z","timestamp":1708664260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1310286\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":34,"alternative-id":["10.3389\/fphar.2024.1310286"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1310286","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"article-number":"1310286"}}